Ukoniq (umbralisib) / TG Therap 
Welcome,         Profile    Billing    Logout  
 7 Diseases   4 Trials   4 Trials   1090 News 
13 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ukoniq (umbralisib) / TG Therap
UNITY-CLL, NCT02612311 / 2015-005758-36: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Checkmark Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Apr 2022 - Apr 2022: Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at iwCLL 2021
More
Terminated
3
603
Europe, US, RoW
Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
02/23
02/23
ULTRA-V, NCT03801525: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL

Hourglass Jan 2021 - Mar 2021 : Completion of enrollment in P2 ULTRA-V trial in combination with umbralisib and venetoclax for CLL
Terminated
2/3
277
US
Ublituximab, TG-1101, Umbralisib, TGR-1202, UKONIQ, Venetoclax, Venclexta®
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/22
12/22
NCT04149821: Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Terminated
2
1
US
Umbralisib, TGR-1202, Ublituximab, TG-1101
Weill Medical College of Cornell University, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL
01/22
06/22
NCT04783415: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Hourglass Jul 2023 - Dec 2023 : From trial in combination with Utuxin and Ukoniq for 1L MCL
Active, not recruiting
2
12
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Ublituximab, LFB-R603, TG-1101, TG-20, TGTX-1101, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
07/22
09/25
NCT03919175: Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Terminated
2
18
US
Umbralisib, TGR-1202, Rituximab, MabThera
Massachusetts General Hospital, TG Therapeutics
Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma Grade 2, Follicular Lymphoma Grade IIIa, Marginal Zone Lymphoma, Marginal Zone B Cell Lymphoma
05/24
05/24
SWOG S1608, NCT03269669: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Active, not recruiting
2
95
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR 1202, TGR-1202, TGR1202, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/25
12/25
NCT04624633: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Active, not recruiting
2
60
US
Acalabrutinib, Calquence, Umbralisib, RP5264, Ublituximab, LFB-R603
Jennifer R. Brown, MD, PhD, AstraZeneca, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
12/26
01/30
NCT05152459: Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Withdrawn
1/2
48
NA
Tazemetostat, E7438, EPZ-6438, EPZ6438, Ublituximab, LFB-R603, TG-1101, TG-20, TGTX-1101, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/24
12/24
NCT02268851: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Checkmark From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Jun 2020 - Jun 2020: From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Checkmark From a trial for r/r CLL or MCL at EHA 2020
Jun 2020 - Jun 2020: From a trial for r/r CLL or MCL at EHA 2020
Checkmark Results in combination with ibrutinib for CLL & MCL
More
Completed
1
45
US
TGR-1202, RP5264, Umbralisib, Ibrutinib, Imbruvica, CRA-032765, PCI-32765
Dana-Farber Cancer Institute, TG Therapeutics, Inc., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
05/18
10/22
NCT02493530: TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Completed
1
60
US
TGR-1202, ruxolitinib, Jakafi
Vanderbilt-Ingram Cancer Center
Myelofibrosis, Polycythemia Vera
03/23
05/24
NCT03283137: Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

Active, not recruiting
1
20
US
TGR-1202, umbralisib, Pembrolizumab, Keytruda
University of Chicago
CLL, B-cell Non Hodgkin Lymphoma
12/27
12/27
TG-1701-101, NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Checkmark From a trial for CLL at EHA 2020
Jun 2020 - Jun 2020: From a trial for CLL at EHA 2020
Terminated
1
172
Europe, RoW
TG-1701, Umbralisib, TGR-1202, Ublituximab, TG-1101
TG Therapeutics, Inc.
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
05/24
05/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
02/25
02/26

Download Options